Annexon Inc ARCHER Phase 2 Results at ASRS Call Transcript
Hello, and welcome to Annexon's conference call. (Operator Instructions) Please be advised this call is being recorded at Annexon's request. I'd now like to turn the call over to Jen Lowe, Chief Financial Officer. You may begin.
Thank you, and good afternoon. Yesterday, we issued a press release outlining results from our ARCHER Phase 2 clinical trial evaluating ANX007 in patients with geographic atrophy that were presented during an oral presentation at the ASRS 2023 Annual Meeting.
The press release, podium presentations and slides used for this conference call are available under the Events and Presentations page within the Investor section of our website.
Today's discussion will include forward-looking statements related to Annexon's current plans and expectations, which are subject to certain risks and uncertainties.
Actual results may differ materially due to various important factors, including those described in the Risk Factors section of our most recent Form 10Q and other SEC filings.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |